No Cover Image

Journal article 893 views 266 downloads

Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics

Benoit Toubhans, Salvatore Gazze, Caroline Bissardon, Sylvain Bohic, Alexandra T. Gourlan, Deya Gonzalez Orcid Logo, Laurent Charlet, Steve Conlan Orcid Logo, Lewis Francis Orcid Logo

Nanomedicine: Nanotechnology, Biology and Medicine, Volume: 29, Start page: 102258

Swansea University Authors: Salvatore Gazze, Deya Gonzalez Orcid Logo, Steve Conlan Orcid Logo, Lewis Francis Orcid Logo

  • 54635.pdf

    PDF | Version of Record

    This is an open access article under the CC BY-NC-ND license.

    Download (2.98MB)

Check full text

DOI (Published version): 10.1016/j.nano.2020.102258

Abstract

High dose selenium acts as a cytotoxic agent, with potential applications in cancer treatment. However, clinical trials have failed to show any chemotherapeutic value of selenium at safe and tolerated doses (<90 μg/day). To enable the successful exploitation of selenium for cancer treatment, we e...

Full description

Published in: Nanomedicine: Nanotechnology, Biology and Medicine
ISSN: 1549-9634
Published: Elsevier BV 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa54635
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2020-08-21T13:12:33Z
last_indexed 2020-12-04T04:09:00Z
id cronfa54635
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2020-12-03T16:58:19.1824265</datestamp><bib-version>v2</bib-version><id>54635</id><entry>2020-07-03</entry><title>Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics</title><swanseaauthors><author><sid>586f1f49652b97c5c3ab99a45a1c58bf</sid><firstname>Salvatore</firstname><surname>Gazze</surname><name>Salvatore Gazze</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>bafdf635eb81280304eedf4b18e65d4e</sid><ORCID>0000-0002-1838-6752</ORCID><firstname>Deya</firstname><surname>Gonzalez</surname><name>Deya Gonzalez</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>0bb6bd247e32fb4249de62c0013b51cb</sid><ORCID>0000-0002-2562-3461</ORCID><firstname>Steve</firstname><surname>Conlan</surname><name>Steve Conlan</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>10f61f9c1248951c1a33f6a89498f37d</sid><ORCID>0000-0002-7803-7714</ORCID><firstname>Lewis</firstname><surname>Francis</surname><name>Lewis Francis</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2020-07-03</date><abstract>High dose selenium acts as a cytotoxic agent, with potential applications in cancer treatment. However, clinical trials have failed to show any chemotherapeutic value of selenium at safe and tolerated doses (&lt;90 &#x3BC;g/day). To enable the successful exploitation of selenium for cancer treatment, we evaluated inorganic selenium nanoparticles (SeNP), and found them effective in inhibiting ovarian cancer cell growth. In both SKOV-3 and OVCAR-3 ovarian cancer cell types SeNP treatment resulted in significant cytotoxicity. The two cell types displayed contrasting nanomechanical responses to SeNPs, with decreased surface roughness and membrane stiffness, characteristics of OVCAR-3 cell death. In SKOV-3, cell membrane surface roughness and stiffness increased, both properties associated with decreased metastatic potential. The beneficial effects of SeNPs on ovarian cancer cell death appear cell type dependent, and due to their low in vivo toxicity offer an exciting opportunity for future cancer treatment.</abstract><type>Journal Article</type><journal>Nanomedicine: Nanotechnology, Biology and Medicine</journal><volume>29</volume><journalNumber/><paginationStart>102258</paginationStart><paginationEnd/><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1549-9634</issnPrint><issnElectronic/><keywords>Selenium; Nanoparticles; Nanomechanics; Ovarian Cancer; Metastasis</keywords><publishedDay>1</publishedDay><publishedMonth>10</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-10-01</publishedDate><doi>10.1016/j.nano.2020.102258</doi><url/><notes/><college>COLLEGE NANME</college><CollegeCode>COLLEGE CODE</CollegeCode><institution>Swansea University</institution><apcterm/><funders>UKRI, MC_PC_19053</funders><lastEdited>2020-12-03T16:58:19.1824265</lastEdited><Created>2020-07-03T15:48:45.6399787</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Benoit</firstname><surname>Toubhans</surname><order>1</order></author><author><firstname>Salvatore</firstname><surname>Gazze</surname><order>2</order></author><author><firstname>Caroline</firstname><surname>Bissardon</surname><order>3</order></author><author><firstname>Sylvain</firstname><surname>Bohic</surname><order>4</order></author><author><firstname>Alexandra T.</firstname><surname>Gourlan</surname><order>5</order></author><author><firstname>Deya</firstname><surname>Gonzalez</surname><orcid>0000-0002-1838-6752</orcid><order>6</order></author><author><firstname>Laurent</firstname><surname>Charlet</surname><order>7</order></author><author><firstname>Steve</firstname><surname>Conlan</surname><orcid>0000-0002-2562-3461</orcid><order>8</order></author><author><firstname>Lewis</firstname><surname>Francis</surname><orcid>0000-0002-7803-7714</orcid><order>9</order></author></authors><documents><document><filename>54635__18012__c4de2ece953541bb93fdcea6f697513a.pdf</filename><originalFilename>54635.pdf</originalFilename><uploaded>2020-08-21T14:11:45.6005116</uploaded><type>Output</type><contentLength>3124944</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This is an open access article under the CC BY-NC-ND license.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>English</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2020-12-03T16:58:19.1824265 v2 54635 2020-07-03 Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics 586f1f49652b97c5c3ab99a45a1c58bf Salvatore Gazze Salvatore Gazze true false bafdf635eb81280304eedf4b18e65d4e 0000-0002-1838-6752 Deya Gonzalez Deya Gonzalez true false 0bb6bd247e32fb4249de62c0013b51cb 0000-0002-2562-3461 Steve Conlan Steve Conlan true false 10f61f9c1248951c1a33f6a89498f37d 0000-0002-7803-7714 Lewis Francis Lewis Francis true false 2020-07-03 High dose selenium acts as a cytotoxic agent, with potential applications in cancer treatment. However, clinical trials have failed to show any chemotherapeutic value of selenium at safe and tolerated doses (<90 μg/day). To enable the successful exploitation of selenium for cancer treatment, we evaluated inorganic selenium nanoparticles (SeNP), and found them effective in inhibiting ovarian cancer cell growth. In both SKOV-3 and OVCAR-3 ovarian cancer cell types SeNP treatment resulted in significant cytotoxicity. The two cell types displayed contrasting nanomechanical responses to SeNPs, with decreased surface roughness and membrane stiffness, characteristics of OVCAR-3 cell death. In SKOV-3, cell membrane surface roughness and stiffness increased, both properties associated with decreased metastatic potential. The beneficial effects of SeNPs on ovarian cancer cell death appear cell type dependent, and due to their low in vivo toxicity offer an exciting opportunity for future cancer treatment. Journal Article Nanomedicine: Nanotechnology, Biology and Medicine 29 102258 Elsevier BV 1549-9634 Selenium; Nanoparticles; Nanomechanics; Ovarian Cancer; Metastasis 1 10 2020 2020-10-01 10.1016/j.nano.2020.102258 COLLEGE NANME COLLEGE CODE Swansea University UKRI, MC_PC_19053 2020-12-03T16:58:19.1824265 2020-07-03T15:48:45.6399787 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Benoit Toubhans 1 Salvatore Gazze 2 Caroline Bissardon 3 Sylvain Bohic 4 Alexandra T. Gourlan 5 Deya Gonzalez 0000-0002-1838-6752 6 Laurent Charlet 7 Steve Conlan 0000-0002-2562-3461 8 Lewis Francis 0000-0002-7803-7714 9 54635__18012__c4de2ece953541bb93fdcea6f697513a.pdf 54635.pdf 2020-08-21T14:11:45.6005116 Output 3124944 application/pdf Version of Record true This is an open access article under the CC BY-NC-ND license. true English https://creativecommons.org/licenses/by/4.0/
title Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics
spellingShingle Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics
Salvatore Gazze
Deya Gonzalez
Steve Conlan
Lewis Francis
title_short Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics
title_full Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics
title_fullStr Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics
title_full_unstemmed Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics
title_sort Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics
author_id_str_mv 586f1f49652b97c5c3ab99a45a1c58bf
bafdf635eb81280304eedf4b18e65d4e
0bb6bd247e32fb4249de62c0013b51cb
10f61f9c1248951c1a33f6a89498f37d
author_id_fullname_str_mv 586f1f49652b97c5c3ab99a45a1c58bf_***_Salvatore Gazze
bafdf635eb81280304eedf4b18e65d4e_***_Deya Gonzalez
0bb6bd247e32fb4249de62c0013b51cb_***_Steve Conlan
10f61f9c1248951c1a33f6a89498f37d_***_Lewis Francis
author Salvatore Gazze
Deya Gonzalez
Steve Conlan
Lewis Francis
author2 Benoit Toubhans
Salvatore Gazze
Caroline Bissardon
Sylvain Bohic
Alexandra T. Gourlan
Deya Gonzalez
Laurent Charlet
Steve Conlan
Lewis Francis
format Journal article
container_title Nanomedicine: Nanotechnology, Biology and Medicine
container_volume 29
container_start_page 102258
publishDate 2020
institution Swansea University
issn 1549-9634
doi_str_mv 10.1016/j.nano.2020.102258
publisher Elsevier BV
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description High dose selenium acts as a cytotoxic agent, with potential applications in cancer treatment. However, clinical trials have failed to show any chemotherapeutic value of selenium at safe and tolerated doses (<90 μg/day). To enable the successful exploitation of selenium for cancer treatment, we evaluated inorganic selenium nanoparticles (SeNP), and found them effective in inhibiting ovarian cancer cell growth. In both SKOV-3 and OVCAR-3 ovarian cancer cell types SeNP treatment resulted in significant cytotoxicity. The two cell types displayed contrasting nanomechanical responses to SeNPs, with decreased surface roughness and membrane stiffness, characteristics of OVCAR-3 cell death. In SKOV-3, cell membrane surface roughness and stiffness increased, both properties associated with decreased metastatic potential. The beneficial effects of SeNPs on ovarian cancer cell death appear cell type dependent, and due to their low in vivo toxicity offer an exciting opportunity for future cancer treatment.
published_date 2020-10-01T04:08:17Z
_version_ 1763753588022050816
score 11.013148

Similar Items